Pathogenic cycle between the endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine and the leukocyte-derived hemoprotein myeloperoxidase.

• Authors: EC von Leitner; KLINKE A; ATZLER D; JL Slocum; LUND N; JT Kielstein; MAAS R; SCHMIDT-HAUPT R; PEKAROVÁ Michaela; HELLWINKEL O; TSIKAS D; LG D Alecy; LAU D; WILLEMS S; KUBALA Lukáš; EHMKE H; MEINERTZ T; BLANKENBERG S; SCHWEDHELM E; CA Gadegbeku; RH Böger; BALDUS S; SYDOW K
• Year of publication: 2011
• Type: Article in Periodical
• Magazine / Source: Circulation
• MU Faculty or unit: Faculty of Science
• web: http://www.ncbi.nlm.nih.gov/pubmed/22082678
• Doi: https://doi.org/11/11/13/CIRCULATIONAHA.111.060541
• Keywords: arteriosclerosis endothelium inflammation leukocytes nitric oxide synthase
• Description: The nitric oxide synthase inhibitor asymmetrical dimethylarginine (ADMA) and the leukocyte-derived hemoprotein myeloperoxidase (MPO) are associated with cardiovascular diseases. Activation of monocytes and polymorphonuclear neutrophils (PMNs) with concomitant release of MPO is regulated in a nitric oxide-dependent fashion. The aim of the study was to investigate a potential 2-way interaction between ADMA and MPO.